Results 131 to 140 of about 1,279,543 (154)

Survodutide for Obesity in Chinese Adults: Phase 3 Randomized Trial Design and Baseline Characteristics (SYNCHRONIZE™-CN). [PDF]

Diabetes Ther
Ji L, Chen L, Cheng Z, Lu Y, Yang Y, Fu F, Zhu Y, Jin L, Kloer IM.   +8 more
europepmc   +1 more source

Nutrient-Stimulated Hormone-Based Therapies: Transforming Obesity Management. [PDF]

Endocrinol Metab (Seoul)
Kwak KH, Jung CH.
europepmc   +1 more source

Multisystem Benefits of GLP-1 Microdosing: A Narrative Review. [PDF]

Cureus
Panlilio MA, Piserchio N, Hennessey M, Torres K, Khan S, Choy L.   +5 more
europepmc   +1 more source

Anti-obesity medications impacting the eye: An emerging concern - a narrative review. [PDF]

World J Methodol
Khullar S, Morya AK, Aggarwal S, Singh A, Sisodiya P, Morya R.   +5 more
europepmc   +1 more source

Novel Therapeutic Strategies for Patients With CKD and Diabetes Mellitus. [PDF]

Kidney Int Rep
Kugathasan L, Katz A, Muskiet MHA, Sridhar VS, Scott J, Yi TW, Cherney DZI.   +6 more
europepmc   +1 more source

Central control of energy balance by amylin and calcitonin receptor agonists and their potential for treatment of metabolic diseases [PDF]

Basic and Clinical Pharmacology and Toxicology, 2020
The prevalence of obesity and associated comorbidities such as type 2 diabetes and cardiovascular disease is increasing globally. Body-weight loss reduces the risk of morbidity and mortality in obese individuals, and thus, pharmacotherapies that induce ...
Thomas A. Lutz, Hannah Louise Zakariassen   +1 more
exaly   +3 more sources

Molecular Signature for Receptor Engagement in the Metabolic Peptide Hormone Amylin [PDF]

ACS Pharmacology and Translational Science, 2018
The pancreatic peptide hormone, amylin, plays a critical role in the control of appetite, and synergizes with other key metabolic hormones such as glucagon-like peptide 1 (GLP-1).
Christopher Walker, Giuseppe Deganutti, Christopher A. Reynolds   +2 more
exaly   +6 more sources

Some of the next articles are maybe not open access.

Related searches:

Does receptor balance matter? – Comparing the efficacies of the dual amylin and calcitonin receptor agonists cagrilintide and KBP-336 on metabolic parameters in preclinical models

Biomedicine and Pharmacotherapy, 2022
K Henriksen
exaly  

A structural basis for amylin receptor phenotype

Science, 2022
Madeleine Fletcher, Radostin Danev, Rachael Johnson   +2 more
exaly  

Design, synthesis and preclinical evaluation of bio-conjugated amylinomimetic peptides as long-acting amylin receptor agonists

European Journal of Medicinal Chemistry, 2022
Wenying Jian, Raymond Patch
exaly